







1

## FRANCE Recent and planned changes in pharmaceutical pricing and reimbursement and overview of the medical devices system

	Changes in pricing	Changes in reimbursement
P H A R M A C E U T I C A L S	<ul> <li>Pricing:</li> <li>Price reduction' policy continues and enables the social security to save about 800M€ both in 2013 and 2014.</li> <li>Among the main changes : <ol> <li>Generics prices were reduced when they were obviously higher than those in Germany, Italy, Spain and UK.</li> <li>A flat price was introduced for off patent PPI (March 2013) and for off patent statins (March 2014).</li> </ol> </li> <li>VAT: <ul> <li>VAT on OTC drugs increased from 7 to 10% on the 1<sup>st</sup> of January 2014.</li> </ul> </li> <li>Margins: <ul> <li>Changes in pharmacists and wholesalers margins are being debated.</li> </ul> </li> <li>Since October 2013 Health Technology Assess the two following conditions are met: <ul> <li>improvement in actual benefit (ASMR) of III (n</li> </ul> </li> </ul>	EPOs removed from the list of drugs reimbursed on top of DRGs (March 2014)
М	Pricing and reimbursement system of medical devices	
E D D E V I C E S	<ul> <li>Continuous positive airway pressure in sleep apnea: We experimented a new tarification system where patients would be refunded for their CPAP device only if they use it significantly enough. This experiment has been stopped by the French supreme court.</li> <li>We created early-access schemes for very innovative medical devices</li> <li>Creation of a positive-list for medical devices that shall be integrated into DRGs tariffs.</li> </ul>	